about
The citius end: world records progression announces the completion of a brief ultra-physiological questCase-control cohort study of patients' perceptions of disability in mastocytosisMasitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KITDepression in patients with mastocytosis: prevalence, features and effects of masitinib therapySuccess in developing regions: world records evolution through a geopolitical prismFrom Oxford to Hawaii ecophysiological barriers limit human progression in ten sport monumentsCaspase activation is required for terminal erythroid differentiationHepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathwaySpecific involvement of caspases in the differentiation of monocytes into macrophagesTLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expressionHsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1Proliferating cell nuclear antigen acts as a cytoplasmic platform controlling human neutrophil survivalLeukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signalingAnalysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cellsKIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisIneffective erythropoiesis in β -thalassemiaControversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?Prevention of infections during primary immunodeficiencyDynamic interaction between STLV-1 proviral load and T-cell response during chronic infection and after immunosuppression in non-human primatesAdvanced systemic mastocytosis: from molecular and genetic progress to clinical practiceMast cell sarcoma: new cases and literature reviewA survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutationErythroferrone: the missing link in β-thalassemia?Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester diseaseFAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of functionEfficacy and Safety of Midostaurin in Advanced Systemic MastocytosisModulation of histidine decarboxylase activity and cytokine synthesis in human leukemic cell lines: relationship with basophilic and/or megakaryocytic differentiationMasitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse modelReducing the global burden of HTLV-1 infection: An agenda for research and action.Mastocytosis in adulthood and neuropsychiatric disorders.A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.[Treatment of systemic mastocytosis].Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells.Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study.Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.Severe prolonged red blood cell aplasia and thrombocytopenia induced by parvovirus B19 infection in a patient with sarcoidosis.Current concepts regarding the HTLV-1 receptor complex.Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature.Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
P50
Q21090101-138A2778-E910-4245-B03D-EBF9242C9515Q21092209-5A64BE8E-884F-40E9-A2B0-EBBB014047C9Q21142738-57C194A5-F0B8-40F9-BF69-8EB22AB71739Q21560915-8F1DA2BB-7C43-4A79-AB85-C58300B6842BQ21562346-4F9D7EFC-FBD3-4435-87D0-6D7E2AED62C1Q21562559-02A900D3-F346-4D39-8263-B1DFFB075782Q24290854-00927871-ED42-4833-AE7C-78C7E79941D1Q24307549-A10170C2-ABB0-4854-B9EF-5338675172C4Q24312229-0A258EA8-9F9C-4BC6-897F-DCAAD67DDBB2Q24315660-E69CC86B-6143-4505-A694-EB668A85882DQ24336627-5E658C97-EB09-4EF0-806B-5652E71673D5Q24595974-4249C0B3-0537-4CC7-AF36-D3C4BB16F739Q24647565-2D7BA173-7BCA-41FC-8121-C1AFD532BDAFQ24675683-5B859C33-ECEA-437C-90A2-5FB2AEF7F6B1Q26830207-BDB5D86D-3135-4CD2-99D5-C6086970B994Q26830255-7E38D56D-3636-434D-890D-6697A21BDF0EQ26852683-440E511E-4810-46C3-A77A-FD04897F6B38Q27008430-430B7ED5-AEC3-4F71-9FB1-B348F225EB11Q27347243-321DDD35-BC97-4BB2-B64B-03BE3015FE84Q28068458-C63CEC9C-9ECB-4D39-AE46-4CC778D4D975Q28071802-EC4F6DCD-A9D3-457B-BEB9-416A85C7CA29Q28246980-9D5B482F-D9EC-4171-8E45-321EDB985A37Q28269009-05B01D1D-B44E-4711-9464-3D2A327B7507Q28291022-6B54B2EA-5A8F-4E1A-A548-77D30A9D1817Q28307801-1BB00C93-784E-43D3-8A75-293DA2C1F183Q28314922-D01E9AB5-CA6D-45FE-8839-C420C3EA40A1Q28369852-FBF9A168-46B9-4BD5-BB52-442AF12FA5F4Q28748653-7D16345E-9EB1-46B7-8220-FC37FE733C84Q30241350-FBC79DE2-CFB7-42EA-8BF1-0BF2C29EB9C3Q30251615-77D3C591-AE5F-4A0A-A2B0-0989B6C723F2Q30496656-65D9DA86-7F13-4042-845D-557FB3D5CC29Q30822114-3D2DC7EC-715F-4A23-84D0-BEF9D43D9D5DQ33182153-8EC6B2E5-BA06-4B8F-B312-AE40303229D0Q33187375-911AB5FC-8EC8-4CFC-AA9D-93D2B896FA20Q33283515-01B24153-CD93-47AD-8ECC-F5CD8257DBECQ33327689-67077D3B-6007-4CA7-A680-50D313FF4EBEQ33346039-F899FCFD-6B49-4868-AAB7-C6E2DAEB997DQ33350169-5C8243F2-F23D-4B26-B390-68F22FF3E01AQ33361545-1D7B3B14-8406-4336-8212-24C4CCAC60E0Q33366619-34827C1F-A69C-4E0B-BE59-02A3B41BA8D6
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Olivier Hermine
@af
Olivier Hermine
@an
Olivier Hermine
@ast
Olivier Hermine
@bar
Olivier Hermine
@br
Olivier Hermine
@ca
Olivier Hermine
@co
Olivier Hermine
@cs
Olivier Hermine
@cy
Olivier Hermine
@da
type
label
Olivier Hermine
@af
Olivier Hermine
@an
Olivier Hermine
@ast
Olivier Hermine
@bar
Olivier Hermine
@br
Olivier Hermine
@ca
Olivier Hermine
@co
Olivier Hermine
@cs
Olivier Hermine
@cy
Olivier Hermine
@da
prefLabel
Olivier Hermine
@af
Olivier Hermine
@an
Olivier Hermine
@ast
Olivier Hermine
@bar
Olivier Hermine
@br
Olivier Hermine
@ca
Olivier Hermine
@co
Olivier Hermine
@cs
Olivier Hermine
@cy
Olivier Hermine
@da
P214
P106
P21
P214
P31
P496
0000-0003-2574-3874
P569
2000-01-01T00:00:00Z
P735
P7859
viaf-190586086